125 related articles for article (PubMed ID: 19196738)
1. The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma.
Lehnerdt GF; Franz P; Bankfalvi A; Grehl S; Kelava A; Nückel H; Lang S; Schmid KW; Siffert W; Bachmann HS
Ann Oncol; 2009 Jun; 20(6):1094-9. PubMed ID: 19196738
[TBL] [Abstract][Full Text] [Related]
2. The AA genotype of the regulatory BCL2 promoter polymorphism ( 938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients.
Bachmann HS; Otterbach F; Callies R; Nückel H; Bau M; Schmid KW; Siffert W; Kimmig R
Clin Cancer Res; 2007 Oct; 13(19):5790-7. PubMed ID: 17908970
[TBL] [Abstract][Full Text] [Related]
3. CC genotype of anti-apoptotic gene BCL-2 (-938 C/A) is an independent prognostic marker of unfavorable clinical outcome in patients with non-small-cell lung cancer.
Javid J; Mir R; Mirza M; Imtiyaz A; Prasant Y; Mariyam Z; Julka PK; Mohan A; Lone M; Ray PC; Saxena A
Clin Transl Oncol; 2015 Apr; 17(4):289-95. PubMed ID: 25257838
[TBL] [Abstract][Full Text] [Related]
4. Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma.
Bachmann HS; Heukamp LC; Schmitz KJ; Hilburn CF; Kahl P; Buettner R; Nückel H; Eisenhardt A; Rübben H; Schmid KW; Siffert W; Eggert A; Schramm A; Schulte JH
Int J Cancer; 2011 Nov; 129(10):2390-9. PubMed ID: 21207420
[TBL] [Abstract][Full Text] [Related]
5. Association of the CC genotype of the regulatory BCL2 promoter polymorphism (-938C>A) with better 2-year survival in patients with glioblastoma multiforme.
El Hindy N; Bachmann HS; Lambertz N; Adamzik M; Nückel H; Worm K; Zhu Y; Sure U; Siffert W; Sandalcioglu IE
J Neurosurg; 2011 Jun; 114(6):1631-9. PubMed ID: 21250804
[TBL] [Abstract][Full Text] [Related]
6. Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia.
Nückel H; Frey UH; Bau M; Sellmann L; Stanelle J; Dürig J; Jöckel KH; Dührsen U; Siffert W
Blood; 2007 Jan; 109(1):290-7. PubMed ID: 16960146
[TBL] [Abstract][Full Text] [Related]
7. ATM, BCL2, and TGFβ Gene Polymorphisms as Radiotherapy Outcome Biomarkers in Head and Neck Squamous Cell Carcinoma Patients.
Agostini LP; Stur E; Garcia FM; Ventorim DP; Dos Reis RS; Dettogni RS; Dos Santos EVW; Peterle GT; Maia LL; Mendes SO; de Carvalho MB; Tajara EH; de Paula F; Dos Santos M; da Silva AMA; Louro ID
Genet Test Mol Biomarkers; 2017 Dec; 21(12):727-735. PubMed ID: 29135311
[TBL] [Abstract][Full Text] [Related]
8. The bcl2 -938CC genotype has poor prognosis and lower survival in renal cancer.
Hirata H; Hinoda Y; Nakajima K; Kikuno N; Suehiro Y; Tabatabai ZL; Ishii N; Dahiya R
J Urol; 2009 Aug; 182(2):721-7. PubMed ID: 19539330
[TBL] [Abstract][Full Text] [Related]
9. Association of the AA genotype of the BCL2 (-938C>A) promoter polymorphism with better survival in ovarian cancer.
Heubner M; Wimberger P; Otterbach F; Kasimir-Bauer S; Siffert W; Kimmig R; Nückel H
Int J Biol Markers; 2009; 24(4):223-9. PubMed ID: 20082279
[TBL] [Abstract][Full Text] [Related]
10. Influence of BCL2-938 C>A promoter polymorphism and BCL2 gene expression on the progression of breast cancer.
Bhushann Meka P; Jarjapu S; Vishwakarma SK; Nanchari SR; Cingeetham A; Annamaneni S; Mukta S; Triveni B; Satti V
Tumour Biol; 2016 May; 37(5):6905-12. PubMed ID: 26662799
[TBL] [Abstract][Full Text] [Related]
11. Polymorphism in apoptotic BAX (-248G>A) gene but not in anti-apoptotic BCL2 (-938C>A) gene and its protein and mRNA expression are associated with cervical intraepithelial neoplasia.
Fernandes AT; Rocha NP; Vendrame E; Russomano F; Grinsztejn BJ; Friedman RK; Pinto AC; Klumb EM; Avvad E; Macedo J; Martínez-Maza O; Bonecini-Almeida Mda G
Apoptosis; 2015 Oct; 20(10):1347-57. PubMed ID: 26272263
[TBL] [Abstract][Full Text] [Related]
12. Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene.
Lehnerdt GF; Franz P; Zaqoul A; Schmitz KJ; Grehl S; Lang S; Schmid KW; Siffert W; Jahnke K; Frey UH
Clin Cancer Res; 2008 Mar; 14(6):1753-8. PubMed ID: 18347176
[TBL] [Abstract][Full Text] [Related]
13. BCL2 genotypes and prostate cancer survival.
Renner W; Langsenlehner U; Krenn-Pilko S; Eder P; Langsenlehner T
Strahlenther Onkol; 2017 Jun; 193(6):466-471. PubMed ID: 28396899
[TBL] [Abstract][Full Text] [Related]
14. Impact of BCL2 polymorphisms on survival in transitional cell carcinoma of the bladder.
Hess J; Stelmach P; Eisenhardt A; Rübben H; Reis H; Schmid KW; Bachmann HS
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1659-1670. PubMed ID: 28417194
[TBL] [Abstract][Full Text] [Related]
15. Influence of BCL2-938C>A and BAX-248G>A promoter polymorphisms in the development of AML: case-control study from South India.
Cingeetham A; Vuree S; Dunna NR; Gorre M; Nanchari SR; Edathara PM; Meka P; Annamaneni S; Digumarthi R; Sinha S; Satti V
Tumour Biol; 2015 Sep; 36(10):7967-76. PubMed ID: 25957891
[TBL] [Abstract][Full Text] [Related]
16. BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility.
Zhang N; Li X; Tao K; Jiang L; Ma T; Yan S; Yuan C; Moran MS; Liang F; Haffty BG; Yang Q
BMC Med Genet; 2011 Apr; 12():48. PubMed ID: 21457555
[TBL] [Abstract][Full Text] [Related]
17. The BCL-2 promoter (-938C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia.
Kaderi MA; Norberg M; Murray F; Merup M; Sundström C; Roos G; Aleskog A; Karlsson K; Axelsson T; Tobin G; Rosenquist R
Leukemia; 2008 Feb; 22(2):339-43. PubMed ID: 18046447
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite GTn-repeat polymorphism in the promoter of heme oxygenase-1 gene is an independent predictor of tumor recurrence in male oral squamous cell carcinoma patients.
Vashist YK; Blessmann M; Trump F; Kalinin V; Kutup A; Schneider C; Gawad K; Kaifi JT; Schmelzle R; Izbicki JR; Yekebas EF
J Oral Pathol Med; 2008 Sep; 37(8):480-4. PubMed ID: 18312299
[TBL] [Abstract][Full Text] [Related]
19. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck.
Chen K; Hu Z; Wang LE; Sturgis EM; El-Naggar AK; Zhang W; Wei Q
Carcinogenesis; 2007 Sep; 28(9):2008-12. PubMed ID: 17693666
[TBL] [Abstract][Full Text] [Related]
20. Modifying effect of mouse double minute-2 promoter variants on risk of recurrence for patients with squamous cell carcinoma of oropharynx.
Zhang Y; Sturgis EM; Li Y; Wei Q; Huang Z; Li G
Sci Rep; 2017 Jan; 7():39765. PubMed ID: 28045062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
